Trials of selective #KRASG12D inhibitors show promise in advanced cancers with G12D mutations, signaling a shift in the treatment landscape — and potential across tumor types and disease stages.
News & Views from Jennifer Knox et al @PMResearch_UHN

Trials of selective #KRASG12D inhibitors show promise in advanced cancers with G12D mutations, signaling a shift in the treatment landscape — and potential across tumor types and disease stages.
News & Views from Jennifer Knox et al @PMResearch_UHN